References
- Adams, A. J., Banister, S. D., Irizarry, L., Trecki, J., Schwartz, M., & Gerona, R. (2017).“Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. The New England Journal of Medicine, 376(3), 235–242. https://doi.org/https://doi.org/10.1056/NEJMoa1610300
- Ahn, K. H., Mahmoud, M. M., Shim, J.-Y., & Kendall, D. A. (2013). Distinct roles of β-Arrestin 1 and β-Arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). The Journal of Biological Chemistry, 288(14), 9790–9800. https://doi.org/https://doi.org/10.1074/jbc.M112.438804
- Alaverdashvili, M., & Laprairie, R. B. (2018). The future of type 1 cannabinoid receptor allosteric ligands. Drug Metabolism Reviews, 50(1), 14–25. https://doi.org/https://doi.org/10.1080/03602532.2018.1428341
- Al-Zoubi, R., Hurst, D., & Reggio, P. (2019). Structural insights from recent CB1 X-ray crystal structures. In W. J. Costaim & R. B. Lapriarie (Eds.), Recent advances in cannabinoid research. IntechOpen. https://doi.org/https://doi.org/10.5772/intechopen.80783
- Ballesteros, J. A., & Weinstein, H. (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Stuart C. Sealfon (Ed.), Methods in neurosciences (Vol. 25, pp. 366–428). Elsevier. https://doi.org/https://doi.org/10.1016/S1043-9471(05)80049-7
- Bauer, M., Chicca, A., Tamborrini, M., Eisen, D., Lerner, R., Lutz, B., Poetz, O., Pluschke, G., & Gertsch, J. (2012). Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. Journal of Biological Chemistry, 287(44), 36944–36967. https://doi.org/https://doi.org/10.1074/jbc.M112.382481
- Beuming, T., & Sherman, W. (2012). Current assessment of docking into GPCR crystal structures and homology models: Successes, challenges, and guidelines. Journal of Chemical Information and Modeling, 52(12), 3263–3277. https://doi.org/https://doi.org/10.1021/ci300411b
- Bian, Y., Jing, Y., Wang, L., Ma, S., Jun, J. J., & Xie, X.-Q. (2019). Prediction of orthosteric and allosteric regulations on cannabinoid receptors using supervised machine learning classifiers. Molecular Pharmaceutics, 16(6), 2605–2615. https://doi.org/https://doi.org/10.1021/acs.molpharmaceut.9b00182
- Chaurasiya, N. D., Zhao, J., Pandey, P., Doerksen, R. J., Muhammad, I., & Tekwani, B. L. (2019). Selective inhibition of human monoamine oxidase B by acacetin 7-methyl ether isolated from Turnera diffusa (Damiana). Molecules, 24(4), 810. https://doi.org/https://doi.org/10.3390/molecules24040810
- Chen, H., Fu, W., Wang, Z., Wang, X., Lei, T., Zhu, F., Li, D., Chang, S., Xu, L., & Hou, T. (2019). Reliability of docking-based virtual screening for GPCR ligands with homology modeled structures: A case study of the angiotensin II type I receptor. ACS Chemical Neuroscience, 10(1), 677–689. https://doi.org/https://doi.org/10.1021/acschemneuro.8b00489
- Chen, W., Shui, F., Liu, C., Zhou, X., Li, W., Zheng, Z., Fu, W., & Wang, L. (2017). Novel peripherally restricted cannabinoid 1 receptor selective antagonist TXX-522 with prominent weight-loss efficacy in diet induced obese mice. Frontiers in Pharmacology, 8, 890. https://doi.org/https://doi.org/10.3389/fphar.2017.00890
- Chin, C.-N., Lucas-Lenard, J., Abadji, V., & Kendall, D. A. (1998). Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. Journal of Neurochemistry, 70(1), 366–373. https://doi.org/https://doi.org/10.1046/j.1471-4159.1998.70010366.x
- Chorvat, R. J., Berbaum, J., Seriacki, K., & McElroy, J. F. (2012). JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorganic & Medicinal Chemistry Letters, 22(19), 6173–6180. https://doi.org/https://doi.org/10.1016/j.bmcl.2012.08.004
- Cluny, N., Vemuri, V., Chambers, A., Limebeer, C., Bedard, H., Wood, J., Lutz, B., Zimmer, A., Parker, L., Makriyannis, A., & Sharkey, K. (2010). A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. British Journal of Pharmacology, 161(3), 629–642. https://doi.org/https://doi.org/10.1111/j.1476-5381.2010.00908.x
- Congreve, M., de Graaf, C., Swain, N. A., & Tate, C. G. (2020). Impact of GPCR structures on drug discovery. Cell, 181(1), 81–91. https://doi.org/https://doi.org/10.1016/j.cell.2020.03.003
- Dhopeshwarkar, A., Murataeva, N., Makriyannis, A., Straiker, A., & Mackie, K. (2017). Two Janus cannabinoids that are both CB2 agonists and CB1 antagonists. The Journal of Pharmacology and Experimental Therapeutics, 360(2), 300–311. https://doi.org/https://doi.org/10.1124/jpet.116.236539
- Díaz, Ó., Dalton, J. A. R., & Giraldo, J. (2019). Revealing the mechanism of agonist-mediated cannabinoid receptor 1 (CB1) activation and phospholipid-mediated allosteric modulation. Journal of Medicinal Chemistry, 62(11), 5638–5654. https://doi.org/https://doi.org/10.1021/acs.jmedchem.9b00612
- Dopart, R., & Kendall, D. A. (2020). Allosteric modulators restore orthosteric agonist binding to mutated CB1 receptors. The Journal of Pharmacy and Pharmacology, 72(1), 84–91. https://doi.org/https://doi.org/10.1111/jphp.13193
- Epand, R. M. (2006). Cholesterol and the interaction of proteins with membrane domains. Progress in Lipid Research, 45(4), 279–294. https://doi.org/https://doi.org/10.1016/j.plipres.2006.02.001
- Fantini, J., & Barrantes, F. (2013). How cholesterol interacts with membrane proteins: An exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. Frontiers in Physiology, 4, 31. https://doi.org/https://doi.org/10.3389/fphys.2013.00031
- Fantini, J., Di Scala, C., Baier, C. J., & Barrantes, F. J. (2016). Molecular mechanisms of protein-cholesterol interactions in plasma membranes: Functional distinction between topological (tilted) and consensus (CARC/CRAC) domains. Chemistry and Physics of Lipids, 199, 52–60. https://doi.org/https://doi.org/10.1016/j.chemphyslip.2016.02.009
- Fay, J. F., & Farrens, D. L. (2012). A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569. The Journal of Biological Chemistry, 287(40), 33873–33882. https://doi.org/https://doi.org/10.1074/jbc.M112.352328
- Fay, J. F., & Farrens, D. L. (2013). The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity. Biochemistry, 52(46), 8286–8294. https://doi.org/https://doi.org/10.1021/bi400842k
- Gado, F., Meini, S., Bertini, S., Digiacomo, M., Macchia, M., & Manera, C. (2019). Allosteric modulators targeting cannabinoid CB1 and CB2 receptors: Implications for drug discovery. Future Medicinal Chemistry, 11(15), 2019–2037. https://doi.org/https://doi.org/10.4155/fmc-2019-0005
- Garai, S., Kulkarni, P. M., Schaffer, P. C., Leo, L. M., Brandt, A. L., Zagzoog, A., Black, T., Lin, X., Hurst, D. P., Janero, D. R., Abood, M. E., Zimmowitch, A., Straiker, A., Pertwee, R. G., Kelly, M., Szczesniak, A.-M., Denovan-Wright, E. M., Mackie, K., Hohmann, A. G., … Thakur, G. A. (2020). Application of fluorine- and nitrogen-walk approaches: Defining the structural and functional diversity of 2-phenylindole class of cannabinoid 1 receptor positive allosteric modulators. Journal of Medicinal Chemistry, 63(2), 542–568. https://doi.org/https://doi.org/10.1021/acs.jmedchem.9b01142
- Glide. (2018). Schrödinger Release 2018-1; LLC.
- Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., & Le Foll, B. (2016). The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. International Journal of Neuropsychopharmacology, 19(12), pyw068. https://doi.org/https://doi.org/10.1093/ijnp/pyw068
- Halgren, T. A. (2009). Identifying and characterizing binding sites and assessing druggability. Journal of Chemical Information and Modeling, 49(2), 377–389. https://doi.org/https://doi.org/10.1021/ci800324m
- Hanson, M. A., Cherezov, V., Griffith, M. T., Roth, C. B., Jaakola, V.-P., Chien, E. Y., Velasquez, J., Kuhn, P., & Stevens, R. C. (2008). A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure, 16(6), 897–905. https://doi.org/https://doi.org/10.1016/j.str.2008.05.001
- Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Krilov, G., Jorgensen, W. L., Abel, R., & Friesner, R. A. (2016). OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, 12(1), 281–296. https://doi.org/https://doi.org/10.1021/acs.jctc.5b00864
- Hollingsworth, S. A., Kelly, B., Valant, C., Michaelis, J. A., Mastromihalis, O., Thompson, G., Venkatakrishnan, A. J., Hertig, S., Scammells, P. J., Sexton, P. M., Felder, C. C., Christopoulos, A., & Dror, R. O. (2019). Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nature Communications, 10(1), 3289. https://doi.org/https://doi.org/10.1038/s41467-019-11062-7
- Horswill, J. G., Bali, U., Shaaban, S., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & Wong Kai In, P. (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. British Journal of Pharmacology, 152(5), 805–814. https://doi.org/https://doi.org/10.1038/sj.bjp.0707347
- Hryhorowicz, S., Kaczmarek-Ryś, M., Andrzejewska, A., Staszak, K., Hryhorowicz, M., Korcz, A., & Słomski, R. (2019). Allosteric modulation of cannabinoid receptor 1 – Current challenges and future opportunities. International Journal of Molecular Sciences, 20(23), 5874. https://doi.org/https://doi.org/10.3390/ijms20235874
- Hua, T., Vemuri, K., Nikas, S. P., Laprairie, R. B., Wu, Y., Qu, L., Pu, M., Korde, A., Jiang, S., Ho, J.-H., Han, G. W., Ding, K., Li, X., Liu, H., Hanson, M. A., Zhao, S., Bohn, L. M., Makriyannis, A., Stevens, R. C., & Liu, Z.-J. (2017). Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature, 547(7664), 468–471. https://doi.org/https://doi.org/10.1038/nature23272
- Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G. W., Wu, Y., Zhao, S., Shui, W., Li, S., Korde, A., Laprairie, R. B., Stahl, E. L., Ho, J.-H., Zvonok, N., Zhou, H., Kufareva, I., Wu, B., Zhao, Q., Hanson, M. A., … Liu, Z.-J. (2016). Crystal structure of the human cannabinoid receptor CB1. Cell, 167(3), 750–762.e14. https://doi.org/https://doi.org/10.1016/j.cell.2016.10.004
- Hurst, D. P., Garai, S., Kulkarni, P. M., Schaffer, P. C., Reggio, P. H., & Thakur, G. A. (2019). Identification of CB1 receptor allosteric sites using force-biased MMC simulated annealing and validation by structure-activity relationship studies. ACS Medicinal Chemistry Letters, 10(8), 1216–1221. https://doi.org/https://doi.org/10.1021/acsmedchemlett.9b00256
- Jaiteh, M., Rodríguez-Espigares, I., Selent, J., & Carlsson, J. (2020). Performance of virtual screening against GPCR homology models: Impact of template selection and treatment of binding site plasticity. PLoS Computational Biology, 16(3), e1007680. https://doi.org/https://doi.org/10.1371/journal.pcbi.1007680
- Jones, D. (2008). End of the line for cannabinoid receptor 1 as an anti-obesity target? Nature Reviews. Drug Discovery, 7(12), 961–962. https://doi.org/https://doi.org/10.1038/nrd2775
- Jourdan, T., Djaouti, L., Demizieux, L., Gresti, J., Vergès, B., & Degrace, P. (2010). CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes, 59(4), 926–934. https://doi.org/https://doi.org/10.2337/db09-1482
- Khurana, L., Mackie, K., Piomelli, D., & Kendall, D. A. (2017). Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. Neuropharmacology, 124, 3–12. https://doi.org/https://doi.org/10.1016/j.neuropharm.2017.05.018
- Krishna Kumar, K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., Kato, H. E., Hilger, D., Maeda, S., Weis, W. I., Farrens, D. L., Dror, R. O., Malhotra, S. V., Kobilka, B. K., & Skiniotis, G. (2019). Structure of a signaling cannabinoid receptor 1-G protein complex. Cell, 176(3), 448–458. e12. https://doi.org/https://doi.org/10.1016/j.cell.2018.11.040
- Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., & Kobilka, B. K. (2013). Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature, 504(7478), 101–106. https://doi.org/https://doi.org/10.1038/nature12735
- Kulkarni, P. M., Kulkarni, A. R., Korde, A., Tichkule, R. B., Laprairie, R. B., Denovan-Wright, E. M., Zhou, H., Janero, D. R., Zvonok, N., Makriyannis, A., Cascio, M. G., Pertwee, R. G., & Thakur, G. A. (2016). Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s). Journal of Medicinal Chemistry, 59(1), 44–60. https://doi.org/https://doi.org/10.1021/acs.jmedchem.5b01303
- Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790–4805. https://doi.org/https://doi.org/10.1111/bph.13250
- Laprairie, R. B., Kulkarni, A. R., Kulkarni, P. M., Hurst, D. P., Lynch, D., Reggio, P. H., Janero, D. R., Pertwee, R. G., Stevenson, L. A., Kelly, M. E. M., Denovan-Wright, E. M., & Thakur, G. A. (2016). Mapping cannabinoid 1 receptor allosteric site(s): Critical molecular determinant and signaling profile of GAT100, a novel, potent, and irreversibly binding probe. ACS Chemical Neuroscience, 7(6), 776–798. https://doi.org/https://doi.org/10.1021/acschemneuro.6b00041
- Laprairie, R. B., Kulkarni, P. M., Deschamps, J. R., Kelly, M. E. M., Janero, D. R., Cascio, M. G., Stevenson, L. A., Pertwee, R. G., Kenakin, T. P., Denovan-Wright, E. M., & Thakur, G. A. (2017). Enantiospecific allosteric modulation of cannabinoid 1 receptor. ACS Chemical Neuroscience, 8(6), 1188–1203. https://doi.org/https://doi.org/10.1021/acschemneuro.6b00310
- LigPrep. (2018). Schrödinger Release 2018-1; LLC.
- Liu, X., Ahn, S., Kahsai, A. W., Meng, K.-C., Latorraca, N. R., Pani, B., Venkatakrishnan, A. J., Masoudi, A., Weis, W. I., Dror, R. O., Chen, X., Lefkowitz, R. J., & Kobilka, B. K. (2017). Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure. Nature, 548(7668), 480–484. https://doi.org/https://doi.org/10.1038/nature23652
- Lomize, M. A., Lomize, A. L., Pogozheva, I. D., & Mosberg, H. I. (2006). OPM: Orientations of Proteins in Membranes database. Bioinformatics, 22(5), 623–625. https://doi.org/https://doi.org/10.1093/bioinformatics/btk023
- Loo, J. S. E., Emtage, A. L., Ng, K. W., Yong, A. S. J., & Doughty, S. W. (2018). Assessing GPCR homology models constructed from templates of various transmembrane sequence identities: Binding mode prediction and docking enrichment. Journal of Molecular Graphics & Modelling, 80, 38–47. https://doi.org/https://doi.org/10.1016/j.jmgm.2017.12.017
- Lu, D., Immadi, S. S., Wu, Z., & Kendall, D. A. (2019). Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. Acta Pharmacologica Sinica, 40(3), 324–335. https://doi.org/https://doi.org/10.1038/s41401-018-0164-x
- Morales, P., & Jagerovic, N. (2020). Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opinion on Drug Discovery, 15(8), 917–930. https://doi.org/https://doi.org/10.1080/17460441.2020.1752178
- Moritz, A. E., Free, R. B., & Sibley, D. R. (2018). Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. Cellular Signalling, 41, 75–81. https://doi.org/https://doi.org/10.1016/j.cellsig.2017.07.003
- Narayanaswami, V., & Dwoskin, L. P. (2017). Obesity: Current and potential pharmacotherapeutics and targets. Pharmacology & Therapeutics, 170, 116–147. https://doi.org/https://doi.org/10.1016/j.pharmthera.2016.10.015
- Nguyen, T., Li, J. X., Thomas, B. F., Wiley, J. L., Kenakin, T. P., & Zhang, Y. (2017). Allosteric modulation: An alternate approach targeting the cannabinoid CB1 receptor. Medicinal Research Reviews, 37(3), 441–474. https://doi.org/https://doi.org/10.1002/med.21418
- Obesity and overweight. (2020). Obesity and overweight Publication. Retrieved 06/01, 2020, from https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
- Oddi, S., Dainese, E., Fezza, F., Lanuti, M., Barcaroli, D., De Laurenzi, V., Centonze, D., & Maccarrone, M. (2011). Functional characterization of putative cholesterol binding sequence (CRAC) in human type-1 cannabinoid receptor. Journal of Neurochemistry, 116(5), 858–865. https://doi.org/https://doi.org/10.1111/j.1471-4159.2010.07041.x
- Oddi, S., Stepniewski, T. M., Totaro, A., Selent, J., Scipioni, L., Dufrusine, B., Fezza, F., Dainese, E., & Maccarrone, M. (2017). Palmitoylation of cysteine 415 of CB1 receptor affects ligand-stimulated internalization and selective interaction with membrane cholesterol and caveolin 1. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1862(5), 523–532. https://doi.org/https://doi.org/10.1016/j.bbalip.2017.02.004
- Oswald, C., Rappas, M., Kean, J., Doré, A. S., Errey, J. C., Bennett, K., Deflorian, F., Christopher, J. A., Jazayeri, A., Mason, J. S., Congreve, M., Cooke, R. M., & Marshall, F. H. (2016). Intracellular allosteric antagonism of the CCR9 receptor. Nature, 540(7633), 462–465. https://doi.org/https://doi.org/10.1038/nature20606
- Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., Westwood, P., Marrs, J., Thomson, F., Cowley, P., Christopoulos, A., Pertwee, R. G., & Ross, R. A. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Molecular Pharmacology, 68(5), 1484–1495. https://doi.org/https://doi.org/10.1124/mol.105.016162
- Priestley, R. S., Nickolls, S. A., Alexander, S. P., & Kendall, D. A. (2015). A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. FASEB Journal, 29(4), 1446–1455. https://doi.org/https://doi.org/10.1096/fj.14-263053
- Prime. (2018). Schrödinger Release 2018-1; LLC.
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004). Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews. Drug Discovery, 3(4), 353–359. https://doi.org/https://doi.org/10.1038/nrd1346
- Sabatucci, A., Tortolani, D., Dainese, E., & Maccarrone, M. (2018). In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor. Biotechnology and Applied Biochemistry, 65(1), 21–28. https://doi.org/https://doi.org/10.1002/bab.1589
- Sachdev, S., Vemuri, K., Banister, S. D., Longworth, M., Kassiou, M., Santiago, M., Makriyannis, A., & Connor, M. (2019). In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. British Journal of Pharmacology, 176(24), 4653–4665.
- Salo, O. M., Lahtela-Kakkonen, M., Gynther, J., Järvinen, T., & Poso, A. (2004). Development of a 3D model for the human cannabinoid CB1 receptor. Journal of Medicinal Chemistry, 47(12), 3048–3057. https://doi.org/https://doi.org/10.1021/jm031052c
- Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature Reviews. Drug Discovery, 16(1), 19–34. https://doi.org/https://doi.org/10.1038/nrd.2016.230
- Schrödinger Release. (2018). 2018-1: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018. Maestro-Desmond Interoperability Tools, Schrödinger.
- Shao, Z., Yan, W., Chapman, K., Ramesh, K., Ferrell, A. J., Yin, J., Wang, X., Xu, Q., & Rosenbaum, D. M. (2019). Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nature Chemical Biology, 15(12), 1199–1205. https://doi.org/https://doi.org/10.1038/s41589-019-0387-2
- Shao, Z., Yin, J., Chapman, K., Grzemska, M., Clark, L., Wang, J., & Rosenbaum, D. M. (2016). High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature, 540(7634), 602–606. https://doi.org/https://doi.org/10.1038/nature20613
- Sherman, W., Beard, H. S., & Farid, R. (2006). Use of an induced fit receptor structure in virtual screening. Chemical Biology & Drug Design, 67(1), 83–84. https://doi.org/https://doi.org/10.1111/j.1747-0285.2005.00327.x
- Shim, J.-Y. (2010). Understanding functional residues of the cannabinoid CB1 receptor for drug discovery. Current Topics in Medicinal Chemistry, 10(8), 779–798. https://doi.org/https://doi.org/10.2174/156802610791164210
- Shim, J. Y., Welsh, W. J., & Howlett, A. C. (2003). Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Biopolymers, 71(2), 169–189. https://doi.org/https://doi.org/10.1002/bip.10424
- Shore, D. M., Baillie, G. L., Hurst, D. H., Navas, F., Seltzman, H. H., Marcu, J. P., Abood, M. E., Ross, R. A., & Reggio, P. H. (2014). Allosteric modulation of a cannabinoid G protein-coupled receptor: Binding site elucidation and relationship to G protein signaling. The Journal of Biological Chemistry, 289(9), 5828–5845. https://doi.org/https://doi.org/10.1074/jbc.M113.478495
- SiteMap. (2018). Schrödinger Release 2018-1; LLC.
- Song, Z.-H., & Bonner, T. I. (1996). A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Molecular Pharmacology, 49(5), 891–896.
- Sriram, K., & Insel, P. A. (2018). G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs? Molecular Pharmacology, 93(4), 251–258. https://doi.org/https://doi.org/10.1124/mol.117.111062
- Srivastava, G., & Apovian, C. (2018). Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon. Current Obesity Reports, 7(2), 147–161. https://doi.org/https://doi.org/10.1007/s13679-018-0300-4
- Stasiulewicz, A., Znajdek, K., Grudzień, M., Pawiński, T., & Sulkowska, J. I. (2020). A guide to targeting the endocannabinoid system in drug design. International Journal of Molecular Sciences, 21(8), 2778. https://doi.org/https://doi.org/10.3390/ijms21082778
- Stornaiuolo, M., Bruno, A., Botta, L., Regina, G. L., Cosconati, S., Silvestri, R., Marinelli, L., & Novellino, E. (2015). Endogenous vs exogenous allosteric modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments. Scientific Reports, 5, 15453. https://doi.org/https://doi.org/10.1038/srep15453
- Thakur, G. A., Nikas, S. P., & Makriyannis, A. (2005). CB1 cannabinoid receptor ligands. Mini Reviews in Medicinal Chemistry, 5(7), 631–640. https://doi.org/https://doi.org/10.2174/1389557054368772
- Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan-Wright, E. M., & Laprairie, R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. British Journal of Pharmacology, 176(10), 1455–1469. https://doi.org/https://doi.org/10.1111/bph.14440
- Towns, J., Cockerill, T., Dahan, M., Foster, I., Gaither, K., Grimshaw, A., Hazlewood, V., Lathrop, S., Lifka, D., Peterson, G. D., Roskies, R., Scott, J. R., & Wilkins-Diehr, N. (2014). XSEDE: Accelerating scientific discovery. Computing in Science & Engineering, 16(5), 62–74. https://doi.org/https://doi.org/10.1109/MCSE.2014.80
- Trillou, C. R., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrié, P. (2003). Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 284(2), R345–R353. https://doi.org/https://doi.org/10.1152/ajpregu.00545.2002
- Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, E., Monlezun, S., Martin-Garcia, E., Kasanetz, F., Baillie, G. L., Panin, F., Cathala, A., Roullot-Lacarrière, V., Fabre, S., Hurst, D. P., Lynch, D. L., Shore, D. M., Deroche-Gamonet, V., Spampinato, U., Revest, J.-M., Maldonado, R., … Piazza, P. V. (2014). Pregnenolone can protect the brain from cannabis intoxication. Science, 343(6166), 94–98. https://doi.org/https://doi.org/10.1126/science.1243985
- Wacker, D., Stevens, R. C., & Roth, B. L. (2017). How ligands illuminate GPCR molecular pharmacology. Cell, 170(3), 414–427. https://doi.org/https://doi.org/10.1016/j.cell.2017.07.009
- Wang, L., Martin, B., Brenneman, R., Luttrell, L. M., & Maudsley, S. (2009). Allosteric modulators of G protein-coupled receptors: Future therapeutics for complex physiological disorders. The Journal of Pharmacology and Experimental Therapeutics, 331(2), 340–348. https://doi.org/https://doi.org/10.1124/jpet.109.156380
- Wei, L., Yuan, Z., Zhao, M., Gu, C., Han, J., & Fu, L. (2018). Inhibition of cannabinoid receptor 1 can influence the lipid metabolism in mice with diet-induced obesity. Biochemistry, 83(10), 1279–1287. https://doi.org/https://doi.org/10.1134/S0006297918100127
- Wold, E. A., Chen, J., Cunningham, K. A., & Zhou, J. (2019). Allosteric modulation of class A GPCRs: Targets, agents, and emerging concepts. Journal of Medicinal Chemistry, 62(1), 88–127. https://doi.org/https://doi.org/10.1021/acs.jmedchem.8b00875
- Zheng, Y., Qin, L., Zacarías, N. V. O., de Vries, H., Han, G. W., Gustavsson, M., Dabros, M., Zhao, C., Cherney, R. J., Carter, P., Stamos, D., Abagyan, R., Cherezov, V., Stevens, R. C., Ijzerman, A. P., Heitman, L. H., Tebben, A., Kufareva, I., & Handel, T. M. (2016). Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature, 540(7633), 458–461. https://doi.org/https://doi.org/10.1038/nature20605